A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

At the end a questionnaire was also administered to investigate patient preference.

Why It Was Studied

Incorrect insulin administration techniques may greatly affect metabolic control in T2DM people.

The secondary endpoint of their study was patients' preference and performance ratings of U-200 lispro.

Who Took Part

The study group was 126 patients.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

126 patients with T2DM were enrolled.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 12 weeks.

They were also assessed for limited joint mobility syndrome (LJMS),defined as limitation in at least two anatomical areas of the dominant upper extremity.

After a 4-weekstructured insulin injection education period.

Half of them were randomized to U-100 lispro, half to U-200 and after 12 weeks they were switched to the other preparation for 12 weeks.

What Was Measured

The secondary endpoint of their study was patients' preference and performance ratings of U-200 lispro.

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Injections, Insulin Lispro and Medication Adherence.

The authors tagged it with the keywords Lispro U-200 and device.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Lispro in 126 patients over 12 weeks.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Expert opinion on drug safety), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.